The global ophthalmic drugs market was valued at $25bn in 2018. The market was dominated by the Retinal Disorder drug submarket which held 43% of the global ophthalmic drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 215-page report you will receive 83 tables and 72 figures– all unavailable elsewhere.
The 215-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Global ophthalmic drugs market revenue forecasts from 2019-2029
Global ophthalmic drugs market revenue forecasts from 2019-2029, by submarket:
- Retinal Disorder Drugs
- Allergic, Inflammatory & Infective Drugs
- Glaucoma Drugs
- Dry Eye Drugs
- Other Ophthalmic Drugs
Revenue forecasts from 2019-2028 of the leading ophthalmic drugs:
- Lumigan & Ganfort
- Other Ophthalmic Drugs
Our report provides an overview, revenue forecast from 2019-2029 of the ophthalmic drugs segment, revenue forecast from 2019-2029 of the leading drugs, product pipeline and SWOT analysis, for these companies:
- Santen Pharmaceuticals
Our study discusses the selected emerging ophthalmic drug manufacturers:
- Aerie Pharmaceuticals
- Aerpio Therapeutics
- Alimera Sciences
- Ampio Pharmaceuticals
- Chengdu Kanghong Pharmaceutical
- Eleven Biotherapeutics
- EyeGate Pharmaceuticals
- Gene Signal
- Icon Bioscience
- OphthaliX /Can-Fite BioPharma
- Otsuka Pharmaceutical
- pSivida Corp.
- RXi Pharmaceuticals
Our report provides these Qualitative Analysis:
- Drivers and Restraints of the Global Ophthalmic Drugs market
- SWOT Analysis of selected leading companies
- Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market
Key questions answered by this report:
- How is the ophthalmic drugs market evolving?
- What is driving and restraining the ophthalmic drugs market?
- What are the market shares of each segment of the overall ophthalmic drugs market in 2018?
- How will each ophthalmic drug submarket grow over the forecast period and how much revenue will these submarkets account for in 2029?
- How will the market shares for each ophthalmic drugs submarket develop from 2018- 2029?
- Which individual therapies will prevail and how will these shifts be responded to?
- What will be the main growth driver of the overall market from 2019-2029?
- Who are the leading players in each regional market and what are their prospects over the forecast period?
- What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
- How will the industry evolve during the period between 2018 and 2029?